Bengaluru, 25th November 2025: Bengaluru-based biotechnology startup CrisprBits Private Limited has raised USD 3 Million through founders, angels & family offices, bringing the company’s valuation to $12 Million.
The current Pre-Series A funding round was led by Spectrum Impact, the family office of Mr. Rajendra Gogri, Chairman and Managing Director of Aarti Industries Ltd. The round also saw participation from the founders and existing investors including Vijay Alreja Family Office (VJ Technologies Group), an early supporter of CrisprBits, whose group company VJ Bio focuses on cell and gene therapy, aligning closely with CrisprBits’ CRISPR-driven innovation goals. The round additionally brought in new investors, including the promoter family of HBL Engineering Ltd., building upon the earlier funds raised from the founders, VJ Technologies Group and C-CAMP (Centre for Cellular and Molecular Platforms).
The new capital will be deployed to scale commercialization of the PathCrisp molecular diagnostics platform, augmenting manufacturing capacity for high-impact tests in human health (e.g., Sickle Cell, Typhoid and Anti-Microbial Resistance), food safety, and animal health. The funding will also accelerate the development of a cutting-edge, CRISPR-driven strain engineering platform, starting with the optimization of processes for biofuel production to address unmet industrial sustainability needs.
CrisprBits is a biotechnology company focused on democratizing synthetic biology to solve challenges in health, food, environment, and energy. Its platforms accelerate detection of drug-resistant infections, enable low-cost genome engineering, and power personalized treatments for rare genetic diseases. CrisprBits technology can be deployed in hospitals, farms, and industries, ensuring timely health interventions, safer food, sustainable agriculture, and climate resilience.
Commenting on the fundraise, Vijay Chandru, CEO, CrisprBits, said, “Our focus has always been on attracting patient capital that shares our visionary goal: to Rewrite Biology and Reimagine the Planet. This funding round provides the fuel for that mission and our team of pioneering CRISPR scientists and results-driven commercial leadership. We are now perfectly positioned to not just launch our products and services in India, but to immediately scale to global markets, ensuring our innovation delivers high-quality, affordable solutions at a truly international scale.”
Mirik Gogri, Principal at Spectrum Impact Family Office, said, “Our family office is excited to invest in CrisprBits. Given our experience in the process industry, we see a clear opportunity for synthetic biology to unlock new industrial frontiers. CrisprBits’ strategy is perfectly poised to deliver multidimensional impact: high-quality diagnostics hitting the market very soon, and the pioneering strain engineering that will enable a more cost-effective future for biochemicals and biofuels. CrisprBits is taking a powerful technology and turning it into immense commercial and societal value. We look forward to working closely with them through this partnership.”
Over the next six months, CrisprBits plans to expand its CRISPR-based diagnostic products into global markets, including Africa and Latin America. The company also plans to strengthen its operations by expanding infrastructure and production capabilities at its diagnostics manufacturing facility. Additionally, the company plans to build a proprietary AI-augmented strain engineering platform for sustainability solutions, including enhancing biofuel production.
About CrisprBits
CrisprBits Pvt Ltd is one of the first Indian CRISPR based companies developing high-quality and affordable solutions in CRISPR-based diagnostics and gene editing. Founded and mentored by five distinguished alumni of BITS Pilani, Prof. Vijay Chandru, Sunil Arora, Prof. Rajeev Kohli, Bharat Jobanputra, and Aditya Sarda, CRISPRBITS is headquartered in NCR, and it operates a 7300 sq. ft. state-of-the-art facility in Bangalore for CRISPR R&D and prototype development.
CrisprBits has three core platforms-
- PathCrisp: This platform is focused on rapid development of accurate, point-of-need disease detection and molecular diagnostics. It is designed for high analytical performance with minimal infrastructure, delivering a sample-to-result time of less than 2.5 hours. Its range of products includes PathCrisp-TyphoidDetect for early detection of Salmonella, PathCrisp-AMRDetect for early detection of major pathogens and antimicrobial resistance (AMR) genes, PathCrisp-SickleDetect for genotype-confirmed identification of sickle cell disease and trait, PathCrisp-FoodSafe for rapid detection of foodborne pathogens from crude food samples, and PathCrisp-OneHealthCattle for on-site surveillance of animal diseases such as LSDV and FMDV.
- EdiCrisp:End-to-end gene editing solutions for precision genome engineering across multiple sectors. Backed by over 25 years of collective expertise in gene editing, it harnesses the power of the indigenous enFnCas9 technology, developed by Institute of Genomics and Integrative Biology, which demonstrates superior on-target precision compared to legacy SpCas9 systems. EdiCrisp supports a wide range of capabilities including gene knockout, knock-in (gene/tag), strain engineering, and functional genomics across diverse organisms such as mammalian cells, bacteria, yeast, plants, and Drosophila.
- CurieCrisp: Preclinical & therapeutics platform that is aimed at bridging the global divide where rare disease models remain limited in the Global North and therapies largely inaccessible in the Global South. Integrating patient-derived iPSC cells, isogenic CRISPR-corrected iPSC lines, and an AI-powered analytics engine, CurieCrisp accelerates drug discovery and preclinical testing for equitable global healthcare innovation.
Website: CrisprBits
